Basic Information

Gene symbol STAT3 Synonyms ADMIO, ADMIO1, APRF, HIES Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description signal transducer and activator of transcription 3

GTO ID GTC2054
Trial ID NCT03819465
Disease Non Small Cell Lung Cancer
Altered gene STAT3
Therapeutic/Target gene Target gene
TherapyASO
Treatment ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx
Co-treatment Durvalumab
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleA Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Year2018
CountryAustria|Belgium|Korea, Republic of|Poland|Russian Federation|Spain|China|Thailand|United States
Company sponsorAstraZeneca
Other ID(s)D933IC00001|2018-001748-74
Vector information
VectorNo vector was used

Clinical Result

Cohort1: Durvalumab
Administration route intravenous injection
Dosage Durvalumab, q4w
Age Adult, Older_Adult
Cohort2: Durvalumab_Danvatirsen
Administration route intravenous injection
Dosage Durvalumab, q4w|Danvatirsen, Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
Age Adult, Older_Adult
Cohort3: Durvalumab_Oleclumab
Administration route intravenous injection
Dosage Durvalumab, q4w|Oleclumab, q2w for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1
Age Adult, Older_Adult
Cohort4: MEDI5752
Administration route intravenous injection
Dosage MEDI5752, q3w
Age Adult, Older_Adult
Cohort5: Durvalumab_Pemetrexed
Administration route intravenous injection
Dosage Durvalumab, q3w for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1|Pemetrexed, Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w)|Carboplatin, Day 1 of each 21-day cycle|Gemcitabine, Days 1 and 8 of each 21-day cycle|Cisplatin, Day 1 of each 21-day cycle|Nab-paclitaxel, Days 1, 8, and 15 of each 21-day cycle
Age Adult, Older_Adult
Cohort6: Durvalumab_Danvatirsen_Pemetrexed
Administration route intravenous injection
Dosage Durvalumab, q3w for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1|Danvatirsen, Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8|Pemetrexed, Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w)|Carboplatin, Day 1 of each 21-day cycle|Gemcitabine, Days 1 and 8 of each 21-day cycle|Cisplatin, Day 1 of each 21-day cycle|Nab-paclitaxel, Days 1, 8, and 15 of each 21-day cycle
Age Adult, Older_Adult
Cohort7: Durvalumab_Oleclumab_Pemetrexed
Administration route intravenous injection
Dosage Durvalumab, q3w for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1|Oleclumab, q3w for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1|Pemetrexed, Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w)|Carboplatin, Day 1 of each 21-day cycle|Gemcitabine, Days 1 and 8 of each 21-day cycle|Cisplatin, Day 1 of each 21-day cycle|Nab-paclitaxel, Days 1, 8, and 15 of each 21-day cycle
Age Adult, Older_Adult
Cohort8: AZD2936
Administration route intravenous injection
Age Adult, Older_Adult
Cohort9: Pemetrexed_AZD2936
Administration route intravenous injection
Dosage Pemetrexed, Day 1 of each 21-day cycle throughout the study|Carboplatin, Day 1 of each 21-day cycle|Cisplatin, Day 1 of each 21-day cycle|AZD2936
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph